Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) reported Q2 2017 earnings this Afternoon, coming in at ($1.15) per share, missing Wall Street’s estimates of ($0.68) per Share. Revenue for the quarter came in at $0.25 million missing the streets estimates
Analyst Coverage For Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)
These are 1 Hold Rating, 4 Buy Ratings .
The current consensus rating for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) is Buy (Score: 2.80) with a consensus target price of $6.50 , a potential (105.70% upside)Recent Insider Trading for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)
- On 11/16/2016 Dennis Langer, Director, sold 23,766 with an average share price of $3.52 per share and the total transaction amounting to $83,656.32.
- On 11/15/2016 Douglas Fambrough, CEO, bought 33,100 with an average share price of $3.71 per share and the total transaction amounting to $122,801.00.
- On 5/12/2016 James B Weissman, Insider, bought 5,000 with an average share price of $3.29 per share and the total transaction amounting to $16,450.00.
- On 11/25/2014 James E Flynn, Insider, sold 321,965 with an average share price of $11.36 per share and the total transaction amounting to $3,657,522.40.
- On 11/7/2014 James E Flynn, Insider, sold 214,164 with an average share price of $9.05 per share and the total transaction amounting to $1,938,184.20.
- On 10/15/2014 James E Flynn, Insider, sold 117,778 with an average share price of $10.86 per share and the total transaction amounting to $1,279,069.08.
Recent Trading for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Shares of Dicerna Pharmaceuticals, Inc. closed the previous trading session at 3.16 down -0.22 -6.51% with 64,859 shares trading hands.